BCRX - BioCryst Pharmaceuticals - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

BCRX is currently covered by 11 analysts with an average price target of $16.31. This is a potential upside of $7.96 (95.33%) from yesterday's end of day stock price of $8.35.

BioCryst Pharmaceuticals's activity chart (see below) currently has 145 price targets and 139 ratings on display. The stock rating distribution of BCRX is 92.31% BUY and 7.69% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 53.73% with an average time for these price targets to be met of 334.07 days.

Highest price target for BCRX is $30, Lowest price target is $11, average price target is $16.36.

Most recent stock forecast was given by TAZEEN AHMAD from BAML on 01-Jul-2025. First documented stock forecast 18-Feb-2014.

Currently out of the existing stock ratings of BCRX, 36 are a BUY (92.31%), 3 are a HOLD (7.69%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$15

$6.86 (84.28%)

$10

1 months 7 days ago
(01-Jul-2025)

4/5 (80%)

$6 (66.67%)

301

Buy

$13

$4.86 (59.71%)

$13

1 months 9 days ago
(30-Jun-2025)

24/26 (92.31%)

$4.04 (45.09%)

468

Buy

$17

$8.86 (108.85%)

$17

1 months 12 days ago
(27-Jun-2025)

3/15 (20%)

$7.64 (81.62%)

348

Hold

$11

$2.86 (35.14%)

$8

3 months 1 days ago
(07-May-2025)

9/12 (75%)

$0.92 (9.13%)

59

Buy

$13

$4.86 (59.71%)

$10

3 months 2 days ago
(06-May-2025)

4/6 (66.67%)

$2.73 (26.58%)

307

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is BCRX (BioCryst Pharmaceuticals) average time for price targets to be met?

On average it took 334.07 days on average for the stock forecasts to be realized with a an average price target met ratio 53.73

Which analyst has the current highest performing score on BCRX (BioCryst Pharmaceuticals) with a proven track record?

ANDREW FEIN

Which analyst has the most public recommendations on BCRX (BioCryst Pharmaceuticals)?

Andrew Fein works at HC WAINWRIGHT and has 17 price targets and 12 ratings on BCRX

Which analyst is the currently most bullish on BCRX (BioCryst Pharmaceuticals)?

Andrew Fein with highest potential upside - $21.86

Which analyst is the currently most reserved on BCRX (BioCryst Pharmaceuticals)?

Justin Kim with lowest potential downside - -$0

BioCryst Pharmaceuticals in the News

BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock

BioCryst Pharmaceuticals BCRX is slated to report its second-quarter 2025 results on Aug. 4, before the opening bell. The Zacks Consensus Estimate for quarterly revenues in the to-be-reported quarter is pegged at $148.85 million. The consensus mark for BCRX’s earnings per share is pinned at 3 cents. In the past 60 days, the Zacks Consensus Estimate...

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his intention to retire on December 31, 2025. The board has appointed Charlie Gayer, currently the company’s chief commercial officer (CCO), as the...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?